COVID-19 Project Team: Difference between revisions
Jump to navigation
Jump to search
Hudakarman (talk | contribs) |
No edit summary |
||
| Line 8: | Line 8: | ||
=== {{AE}} === | === {{AE}} === | ||
{{Multicol}} | |||
* The name of the leaders are written in '''bold''': | * The name of the leaders are written in '''bold''': | ||
'''COVID-19 constant Update''" | |||
[[User:Aisha Adigun|Aisha Adigun, M.D]] | |||
'''Cardiovascular Disorders of COVID-19 Team Members''' | '''Cardiovascular Disorders of COVID-19 Team Members''' | ||
*[[User:Behjat|Alieh Bahjat, M.D.]] | *[[User:Behjat|Alieh Bahjat, M.D.]] | ||
*'''[[User:Mandana Chitsazan|Mandana Chitsazan, M.D.]]''' | *'''[[User:Mandana Chitsazan|Mandana Chitsazan, M.D.]]''' | ||
| Line 61: | Line 61: | ||
*[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | *[[User:NNikravangolsefid|Nasrin Nikravangolsefid, M.D, MPH]] | ||
*[[User:MydahSajid|Mydah Sajid, M.D.]] | *[[User:MydahSajid|Mydah Sajid, M.D.]] | ||
{{ColBreak}} | |||
'''Neurologic Disorders and COVID-19 Team Members''' | '''Neurologic Disorders and COVID-19 Team Members''' | ||
*'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | *'''[[User:Fahimeh Shojaei |Fahimeh Alsadat Shojaei, M.D.]]''' | ||
| Line 81: | Line 81: | ||
*[[User:Rija Gul|Rija Gul, M.B.B.S]] | *[[User:Rija Gul|Rija Gul, M.B.B.S]] | ||
*Rana Aljebzi (not trained yet) | *Rana Aljebzi (not trained yet) | ||
'''Endocrinology and COVID-19''' | '''Endocrinology and COVID-19''' | ||
*'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]''' | *'''[[User:Tayyaba Ali|Tayyaba Ali, M.D.]]''' | ||
'''Infectious diseases and COVID-19''' | '''Infectious diseases and COVID-19''' | ||
*Harmeet, MD | *Harmeet, MD | ||
*Zaida, MD | *Zaida, MD | ||
{{ColBreak}} | |||
Revision as of 21:16, 12 August 2020
| COVID-19 Project |
|---|
| Introduction |
| Team |
| Meetings' Summary |
| Topics |
| Ongoing Clinical Trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]